1.Is radioimmunotherapy a 'magic bullet'?.
Korean Journal of Hematology 2012;47(2):85-86
No abstract available.
Radioimmunotherapy
2.Stability of 188Re Labeled Antibody for Radioimmunotherapy and the Effect of Stabilizing Agents.
Young Soo CHANG ; Bo Kwang KIM ; Jae Min JEONG ; June Key CHUNG ; Seung Jin LEE ; Dong Soo LEE ; Myung Chul LEE
Korean Journal of Nuclear Medicine 2002;36(3):195-202
No abstract available.
Excipients*
;
Radioimmunotherapy*
3.Radioimmunotherapy (II): Clinical Application.
Gi Jeong CHEON ; Hye Jin KANG ; Sang Moo LIM
Nuclear Medicine and Molecular Imaging 2006;40(2):74-81
Molecular targeting may be defined as the specific concentration of a diagnostic or therapeutic tracer by its interaction with a molecular species that is distinctly present or absent in a disease state. Monoclonal antibody (mAb) is one of the successful agents for targeted therapy in cancer. To enhance the therapeutic effect, the concept of targeting radionuclides to tumors using radiolabeled mAbs against tumor-associated antigens, radioimmunotherapy, was proposed. The efficacy of radioimmunotherapy, however, has to be further optimized. Several strategies to improve targeting of tumors with radiolabeled mAbs have been developed, such as the use of mAb fragments, the use of high-affinity mAbs, the use of labeling techniques that are stable in vivo, active removal of the radiolabeled mAb from the circulation, and pretargeting strategies. Until now, however, there are many kinds of obstacles to be solved in the use of mAb for the targeted therapy. Major technical challenges to molecular targeting are related to the rapid and specific delivery of tracers to the target, the elimination of unwanted background activity, and the development of more specific targets to create a cytocidal effect. Further development of this field will be determined by success in solving these challenges.
Radioimmunotherapy*
;
Radioisotopes
4.Fundamental principle of radiotherapy with radio active-isotopes
Journal of Medical and Pharmaceutical Information 2003;10():9-12
Radiotherapy with radioactive-isotopes was used in the treating of some thyroidal diseases, malignant diseases of blood, and cancer… The efficacy of this method is depended on radiation, radiating energy, destiny of in vivo transformation of radioactive-isotopes, half-life disintegration time, and characteristics of treated cells and tissues. Author introduces some diseases treated by radiotherapy such as Basedow’s disease, simple goiter, polycythemia, and chronic disease of white blood cell… In addition author introduces some methods such as treating by radioactive colloid and radioimmunotherapy
Radiotherapy
;
Radioimmunotherapy
;
Radiation
5.Novel biological strategies to enhance the radiation therapeutic ratio
Jae Ho KIM ; Kenneth A JENROW ; Stephen L BROWN
Radiation Oncology Journal 2018;36(3):172-181
Successful anticancer strategies require a differential response between tumor and normal tissue (i.e., a therapeutic ratio). In fact, improving the effectiveness of a cancer therapeutic is of no clinical value in the absence of a significant increase in the differential response between tumor and normal tissue. Although radiation dose escalation with the use of intensity modulated radiation therapy has permitted the maximum tolerable dose for most locally advanced cancers, improvements in tumor control without damaging normal adjacent tissues are needed. As a means of increasing the therapeutic ratio, several new approaches are under development. Drugs targeting signal transduction pathways in cancer progression and more recently, immunotherapeutics targeting specific immune cell subsets have entered the clinic with promising early results. Radiobiological research is underway to address pressing questions as to the dose per fraction, irradiated tumor volume and time sequence of the drug administration. To exploit these exciting novel strategies, a better understanding is needed of the cellular and molecular pathways responsible for both cancer and normal tissue and organ response, including the role of radiation-induced accelerated senescence. This review will highlight the current understanding of promising biologically targeted therapies to enhance the radiation therapeutic ratio.
Aging
;
Radiobiology
;
Radioimmunotherapy
;
Signal Transduction
;
Tumor Burden
6.Radioimmunotherapy (I): Development of Radioimmunoconjugates.
Nuclear Medicine and Molecular Imaging 2006;40(2):66-73
Monoclonal antibodies are designed to bind specifically to certain antigen, give therapeutic effect to the target and to be produced in large scale with homogeneity. The monoclonal antibodies conjugated with radionuclide can deliver therapeutic irradiation to the target, and showed successful results in certain malignancies, which is known as radioimmunotherapy. The target-to-background ratio depends on the antigen expression in the target and normal tissues, which is related to the therapeutic efficacy and toxicity in radioimmunotherapy. For the solid tumor beta-ray energy should be high, but lower beta energy is better for the hematological malignancies. I-131 is widely used in thyroid cancer with low cost and high availability. Labeling monoclonal antibody with I-131 is relatively simple and reproducible. Some preclinical data for the I-131 labeled monoclonal antibodies including acute toxicity and efficacy are available from already published literatures. In KIRAMS, physician sponsored clinical trial protocols using Rituximab, KFDA approved anti-CD20 chimeric monoclonal antibody and I-131 were approved by KFDA and currently are ongoing.
Antibodies, Monoclonal
;
Hematologic Neoplasms
;
Immunoconjugates*
;
Radioimmunotherapy*
;
Thyroid Neoplasms
;
Rituximab
7.Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy
Hyeon gi KIM ; A. Ram YU ; Jae Joon LEE ; Yong Jin LEE ; Sang Moo LIM ; Jin Su KIM
Korean Journal of Nuclear Medicine 2019;53(4):235-241
Tumor interstitial pressure is a fundamental feature of cancer biology. Elevation in tumor pressure affects the efficacy of cancer treatment and results in the heterogenous intratumoral distribution of drugs and macromolecules. Monoclonal antibodies (mAb) play a prominent role in cancer therapy and molecular nuclear imaging. Therapy using mAb labeled with radionuclides—also known as radioimmunotherapy (RIT)—is an effective form of cancer treatment. RIT is clinically effective for the treatment of lymphoma and other blood cancers; however, its clinical use for solid tumor was limited because their high interstitial pressure prevents mAb from penetrating into the tumor. This pressure can be decreased using anti-cancer drugs or additional external therapy. In this paper, we reviewed the intratumoral pressure using direct tumor-pressure measurement strategies, such as the wick-in-needle and pressure catheter transducer method, and indirect tumor-pressure measurement strategies via magnetic resonance.
Antibodies, Monoclonal
;
Biology
;
Catheters
;
Lymphoma
;
Methods
;
Radioimmunotherapy
;
Transducers
8.In Vitro Properties and Biodistribution of Tc-99m and Re-188 Labeled Monoclonal Antibody CEA79.4.
Myung Chul LEE ; June Key CHUNG ; Dong Soo LEE ; Jae Min JEONG ; Young Soo CHANG ; Mee Kyoung HONG ; Jeong Seok YEO ; Yong Jin LEE ; Kyung Min KIM ; Seung Jin LEE
Korean Journal of Nuclear Medicine 1998;32(6):516-524
PURPOSE: Radiolabeled CEA79.4 antibody has a possibility to be used in radioimmunoscintigraphy or radioimmunotheraphy of cancer. We investigated the in vitro properties and biodistribution of CEA79.4 antibody labeled with Re-188 or Tc-99m. MATERIALS AND METHODS: CEA79.4 was reduced by 2-mercaptoethanol to produce-SH reside, and was labeled with Re-188 or Tc-99m. For direct labeling of Tc-99m, methylene-diphosphonate was used as transchelating agent. CEA79.4 in 50 mM Acetate Buffered Saline (ABS, pH 5.3) was labeled with Re-188, using stannous tartrate as reducing agent. In order to measure immunoreactivity and the affinity constant of radiolabeled antibody, cell binding assay and Scatchard analysis using human colon cancer cells SNU-C4, were performed. Biodistribution study of labeled CEA79.4 was carried out at 1, 14 and 24 hr in ICR mice. RESULTS:. Labeling efficiencies of Tc-99m and Re-188 labeled antibodies were 92.4+/-5.9% and 84.7+/-4.6%, respectively. In vitro stability of Tc-99m-CEA79.4 in human serum was higher than Re-188-CEA79.4. Immunoreactivity and affinity constant of Tc-99m-CEA79.4 were 59.2% and 6.59x109 M-1, respectively, while those of Re-188-CEA79.4 were 41.6% and 4.2x109 M-1, respectively. After 24 hr of administrations of Re-188 and Tc-99m labeled antibody, the remaining antibody, the remaining antibodies in blood were 6.32 and 9.35% ID/g respectively. The biodistribution of each labeled antibody in other organs was similar because they did not accumulate in non-targeted organs. CONCLUSION: In vitro properties and biodistribution of Re-188-CEA79.4 were similar to those of Tc-99m-CEA79.4. It appears that Re-188-CEA79.4 can be used as a suitable agent for radioimmunotherapy.
Animals
;
Antibodies
;
Colonic Neoplasms
;
Humans
;
Hydrogen-Ion Concentration
;
Mercaptoethanol
;
Mice
;
Mice, Inbred ICR
;
Radioimmunodetection
;
Radioimmunotherapy
9.mage-Based Assessment and Clinical Significance of Absorbed Radiation Dose to Tumor in Repeated High-Dose (131)I Anti-CD20 Monoclonal Antibody (Rituximab) Radioimmunotherapy for Non-Hodgkin's Lymphoma.
Byung Hyun BYUN ; Kyeong Min KIM ; Sang Keun WOO ; Tae Hyun CHOI ; Hye Jin KANG ; Dong Hyun OH ; Byeong Il KIM ; Gi Jeong CHEON ; Chang Woon CHOI ; Sang Moo LIM
Nuclear Medicine and Molecular Imaging 2009;43(1):60-71
PURPOSE: We assessed the absorbed dose to the tumor (Dosetumor) by using pretreatment FDG-PET and whole-body (WB) planar images in repeated radioimmunotherapy (RIT) with 131I rituximab for NHL. MATERIALS AND METHODS: Patients with NHL (n=4) were administered a therapeutic dose of (131)I rituximab. Serial WB planar images after RIT were acquired and overlaid to the coronal maximum intensity projection (MIP) PET image before RIT. On registered MIP PET and WB planar images, 2D-ROIs were drawn on the region of tumor (n=7) and left medial thigh as background, and Dosetumor was calculated. The correlation between Dosetumor and the CT-based tumor volume change after RIT was analyzed. The differences of Dosetumor and the tumor volume change according to the number of RIT were also assessed. RESULTS: The values of absorbed dose were 397.7+/-646.2cGy (53.0~2853.0cGy). The values of CT-based tumor volume were 11.3+/-9.1 cc (2.9~34.2cc), and the % changes of tumor volume before and after RIT were -29.8+/-44.3% (-100.0%~+42.5%), respectively. Dosetumor and the tumor volume change did not show the linear relationship (p>0.05). Dosetumor and the tumor volume change did not correlate with the number of repeated administration (p>0.05). CONCLUSION: We could determine the position and contour of viable tumor by MIP PET image. And, registration of PET and gamma camera images was possible to estimate the quantitative values of absorbed dose to tumor.
Antibodies, Monoclonal, Murine-Derived
;
Gamma Cameras
;
Humans
;
Lymphoma
;
Lymphoma, Non-Hodgkin
;
Radioimmunotherapy
;
Thigh
;
Tumor Burden
;
Rituximab
10.Review of Radionuclide Treatment for Neuroendocrine Tumors.
Nuclear Medicine and Molecular Imaging 2006;40(2):90-95
Neuroendocrine tumors (NETs) consist of a heterogeneous group of tumors that are able to uptake neuroamine and/or specific receptors, such as somatostatin receptors, which can play important roles of the localization and treatment of these tumors. When considering therapy with radionuclides, the best radioligand should be carefully investigated. 131I-MIBG and beta-particle emitter labeled somatostatin analogs are well established radionuclide therapy modalities for NETs. 111In, 90Y and 177Lu radiolabeled somatostatin analogues have been used for treatment of NETs. Further, radionuclide therapy modalities, for example, radioimmunotherapy, radiolabeled peptides such as minigastrin are currently under development and in different phases of clinical investigation. For all radionuclides used for therapy, long-term and survival statistics are not yet available and only partial tumour responses have been obtained using 131I-MIBG and 111In-octreotide. Experimental results using 90Y-DOTA-lanreotide as well as 90Y-DOTA-D-Phe1-Tyr3-octreotide and/or 177Lu-DOTA-Tyr3-octreotate have indicated the possible clinical potential of radionuclides receptor-targeted radiotherapy. It may be hoped that the efficacy of radionuclide therapy will be improved by co-administration of chemotherapeutic drugs whose antitumoral properties may be synergistic with that of irradiation.
3-Iodobenzylguanidine
;
Hope
;
Neuroendocrine Tumors*
;
Peptides
;
Radioimmunotherapy
;
Radioisotopes
;
Radiotherapy
;
Receptors, Somatostatin
;
Somatostatin